Israeli VC Giant Pitango Raises $300 Million for New Early-Stage and HealthTech Funds
- ByStartupStory | November 7, 2025
Pitango Venture Capital, one of Israel’s most prominent and long-established investment firms, has successfully closed $300 million in fresh capital for its latest early-stage and healthcare-focused funds. The new fundraising, announced November 6, 2025, comprises two vehicles—Pitango First, targeting technology startups in artificial intelligence (AI), infrastructure, quantum, cybersecurity, and cloud; and Pitango HealthTech, dedicated to digital health, medical devices, AI in healthcare, and pharmaceuticals.
Pitango is regarded as a pillar of the Israeli venture scene, with over $3 billion under management and a legacy that includes more than 300 portfolio companies and nearly 100 successful exits through IPOs and strategic acquisitions. Its recent portfolio highlights include the IPO of Via, a $1 billion round for PsiQuantum, and the exit of Vertos, underscoring its reputation for identifying and nurturing high-potential startups.
The Pitango First team, led by Eyal Niv, Dr. Ayal Itzkovitz, Gad Huldai, and Yair Cassuto, is embarking on their third consecutive fund together. The group has already made investments in emerging sectors like generative AI and industrial automation, backing early-stage ventures such as AAI, GammaTime, and Apprentice.AI, while emphasizing support for first-time founders. The HealthTech fund, led by Ittai Harel, Hila Karah, and Dr. Jonathan Glazer, has invested in diverse companies including QuantHealth, Somite, LeaFix Medical, and Guardoc.
Pitango’s approach stands out not only for its financial commitment but also for its innovative investment model designed to accelerate funding in its core markets. With the highest number of Israeli portfolio companies generating over $100 million in annual revenue, the firm now leads in domestic AI and quantum tech adoption, as well as in scaling healthcare innovation.
The new funds launch during a challenging funding climate but signal continued confidence in Israel’s capacity to deliver next-generation technology solutions. Demand for Israeli innovation remains robust, particularly in transformative domains such as AI, healthcare, fintech, and cloud infrastructure, where global investors increasingly seek novel growth opportunities.
In summary, Pitango’s latest $300 million fundraising strengthens its position as a trailblazer in Israeli and global venture capital. The capital infusion will enable Pitango to amplify support for early-stage tech and healthcare innovators, helping build the next wave of dominant unicorns amid evolving digital and medical frontiers.
Follow Startup Story
Related Posts
